E4021, a selective phosphodiesterase 5 inhibitor, potentiates the vasodilator effect of inhaled nitric oxide in isolated perfused rat lungs

Journal of Cardiovascular Pharmacology

Volumn 33, Issue 4, 1999, Pages 619-624

  Ohnishi, Masahiro ^a   Oka, Masahiko ^a   Muramatsu, Masashi ^a   Sato, Koichi ^a   Kira, Shiro ^a   Fukuchi, Yoshinosuke ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Cyclic 3'5' guanosine monophosphate; Phosphodiesterase; Pulmonary hypertension; Pulmonary vascular tone

Indexed keywords

1 [6 CHLORO 4 (3,4 METHYLENEDIOXYBENZYLAMINO) 2 QUINAZOLINYL] 4 PIPERIDINECARBOXYLIC ACID; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; CYCLIC GMP; ISOPRENALINE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE INHIBITOR;

ADOLESCENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; INHALATIONAL DRUG ADMINISTRATION; ISOLATED LUNG; LUNG BLOOD VESSEL; MALE; NONHUMAN; PERFUSION PRESSURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; REGIONAL PERFUSION; VASODILATATION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; 3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADMINISTRATION, INHALATION; ANIMALS; BRONCHODILATOR AGENTS; CYCLIC GMP; DRUG SYNERGISM; HYPERTENSION, PULMONARY; ISOPROTERENOL; LUNG; MALE; NITRIC OXIDE; NITROPRUSSIDE; PERFUSION; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERIDINES; PULMONARY CIRCULATION; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; VASOCONSTRICTION; VASODILATION;

EID: 0032964336     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199904000-00015     Document Type: Article

References (21)

1. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet 1991;338:1173-4
2. Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator reversing hypoxic pulmonary hypertension. Circulation 1991;83:2038-47.
3. Pearl RG. Inhaled nitric oxide: the past, the present, and the future. Anesthesiohgy 1993;78:413-6.
4. Zapol WM, Rimar S, Gillis N, Marletta M, Bosken CH. Nitric oxide and the lung: NHLBI workshop summary. Am J Respir Crit Care Med 1994;149:1375-80.
5. Troncy E, Francceur M, Blaaise G. Inhaled nitric oxide: clinical applications, indications, and toxicology. Can J Anaesth 1997;44:973-88.
6. Dinerman JL, Lowenstein CJ, Snyder SH. Molecular mechanisms of nitric oxide regulation: potential relevance to cardiovascular disease. Circ Res 1993;73:217-22.
7. Anggard E. Nitric oxide: mediator, murderer, and medicine. Lancet 1994;343:1199-206.
8. A inhibitors. Drug News Perspect 1993;6:150-6.
9. Polson JB. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol 1996;36:403-27.
10. Ichinose F, Adrie C, Hurford WE, Zapol WM. Prolonged pulmonary vasodilator action of inhaled nitric oxide by zaprinast in awake lambs. J Appl Physiol 1995;78:1288-95.
11. Thusu KG, Morin FC III, Russel JA, Steinhorn RH. The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide. Am J Respir Crit Care Med 1995;152:1605-10.
12. Kinsella JP, Torielli F, Ziegler JW, Ivy DD, Abman SH. Dipyridamole augmentation of response to nitric oxide. Lancet 1995;346:647-8.
13. Kodama K, Adachi H, Mori N, Saito I. Effects of a novel, selective and potent phosphodiesterase type V inhibitor, E4021, on myocardial ischemia in guinea pigs. Eur J Pharmacol 1994;263:93-9.
14. Saeki T, Adachi H, Takase Y, Yoshitake S, Souda S, Saito I. A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery. J Pharmacol Exp Ther 1995;272:825-31.
15. Oka M, Hasunuma K, Webb SA, Stelzner TJ, Rodman DM, McMurtry IF. EDRF suppresses an unidentified vasoconstrictor mechanism in hypertensive rat lungs. Am J Physiol 1993;264:L587-97.
16. Barnes PJ, Liu SF. Regulation of pulmonary vascular tone. Pharmacol Rev 1995;47:87-131.
17. Miyahara M, Ito M, Ito H, et al. Isoenzymes of cyclic nucleotide phosphodiesterase in the human aorta: characterization and the effects of E4021. Eur J Pharmacol 1995;284:25-33.
18. Cohen AH, Hanson K, Morris K, et al. Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest 1996;97:172-9.
19. Yamaguchi K, Oka M, Nishino M, Hanasato N, Kira S, Fukuchi Y. E4021, a cGMP phosphodiesterase inhibitor, is a selective pulmonary vasodilator in chronically hypoxic pulmonary hypertensive rats. J Jpn Respir Soc 1998;36:23-8.
20. Gerlach H, Rossiant R, Pappart D, Falke KJ. Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome. Eur J Clin Invest 1993;23:499-502.
21. Rich GF, Roos CM, Anderson SM, Urich DC, Daugherty MO, Johns RA. Inhaled nitric oxide: dose response and the effects of blood in the isolated rat lung. J Appl Physiol 1993;75:1278-84.